-

ABIONYX Pharma: Half-Yearly Report on the Liquidity Contract With TP ICAP (Europe) SA

PARIS--(BUSINESS WIRE)--Regulatory News:

Under the liquidity contract entered into by ABIONYX Pharma (Paris:ABNX) with TP ICAP (Europe) SA, the following assets were included in the liquidity account at June 30, 2025:

  • Number of shares: 162,298
  • Cash balance: 86,279.52 €

During the 1st half of 2025, a total of :

PURCHASE

223,631 shares

275,707.78 €

253 transactions

SALE

214,077 shares

272,643.70 €

226 transactions

As a reminder, at the half-yearly balance sheet date of December 31, 2024, the following assets were included in the liquidity account:

  • Number of shares: 152,744 shares
  • Cash balance: 90,498.64 €

When the liquidity contract was set up, the following resources were made available:

  • Number of shares: 131,000 shares
  • Cash balance: 40,801.20 €

ANNEX H1 2025

Purchases

Sales

ABNX FP

number of
transactions

Number of
shares

Capital in
EUR

number of
transactions

Number of
shares

Capital in EUR

Total

253

223,631

275,707.78

226

214,077

272 ,643.696

20250101

0

0

0,00

0

0

0,00

20250102

1

1

1,20

1

1

1,20

20250103

4

4 731

5 598,24

1

1

1,20

20250106

2

2 151

2 555,39

1

1

1,19

20250107

2

2 091

2 475,76

2

2

2,41

20250108

1

1

1,21

6

16 781

20 838,45

20250109

1

1

1,28

3

4 091

5 261,22

20250110

5

6 674

8 375,50

1

1

1,30

20250113

2

2 321

2 915,20

1

1

1,28

20250114

2

2 251

2 827,26

1

1

1,26

20250115

3

2 283

2 834,77

2

1 364

1 732,25

20250116

2

2 181

2 708,83

2

54

68,58

20250117

1

1

1,27

5

12 861

16 681,79

20250120

2

2 411

3 134,32

3

4 051

5 396,12

20250121

4

5 141

6 583,61

1

1

1,29

20250122

2

2 391

3 003,11

1

1

1,27

20250123

2

2 321

2 910,53

2

98

125,61

20250124

2

2 251

2 827,28

2

3

3,85

20250127

3

3 001

3 731,25

1

1

1,25

20250128

1

1

1,24

1

1

1,24

20250129

4

3 726

4 523,13

1

1

1,24

20250130

2

300

362,40

1

1

1,21

20250131

2

16

19,30

4

8 891

11 103,15

20250203

3

3 141

3 830,03

2

72

90,00

20250204

2

2 251

2 710,21

1

1

1,21

20250205

1

1

1,22

2

2

2,44

20250206

2

2 181

2 630,31

1

1

1,23

20250207

2

2 131

2 544,42

1

1

1,20

20250210

1

1

1,22

2

2

2,44

20250211

1

1

1,20

1

1

1,20

20250212

1

1

1,20

4

6 289

7 736,41

20250213

3

3 011

3 659,43

2

2

2,49

20250214

1

1

1,23

2

2

2,46

20250217

2

250

300,50

3

4 441

5 480,40

20250218

1

1

1,24

4

4 329

5 463,59

20250219

3

3 201

3 941,54

2

392

494,68

20250220

1

1

1,33

6

15 961

21 228,13

20250221

1

1

1,31

2

738

972,68

20250224

3

3 621

4 697,72

1

1

1,32

20250225

1

1

1,33

5

11 351

15 354,69

20250226

3

3 811

5 134,77

3

3 591

4 962,95

20250227

3

3 821

5 140,51

1

1

1,35

20250228

4

5 691

7 466,21

1

1

1,35

20250303

1

1

1,30

6

12 891

17 168,66

20250304

4

6 181

8 071,89

2

2

2,69

20250305

2

2

2,54

2

1 559

2 023,55

20250306

2

2 921

3 727,21

1

1

1,29

20250307

3

3 871

4 913,61

1

1

1,27

20250310

3

3 721

4 715,77

1

1

1,27

20250311

4

5 571

6 855,74

1

1

1,26

20250312

1

1

1,24

1

1

1,24

20250313

2

424

517,30

3

4 051

5 072,04

20250314

3

3 571

4 439,97

1

1

1,25

20250317

2

2 561

3 129,56

1

1

1,24

20250318

1

1

1,24

1

1

1,24

20250319

2

2 481

3 031,78

1

1

1,22

20250320

2

2 411

2 941,43

3

4 231

5 297,39

20250321

1

1

1,26

7

19 891

25 919,78

20250324

3

3 627

4 672,00

2

972

1 281,10

20250325

2

2 901

3 690,09

1

1

1,29

20250326

1

1

1,29

1

1

1,29

20250327

1

1

1,28

1

1

1,28

20250328

1

1

1,28

1

1

1,28

20250331

2

1 862

2 346,13

1

1

1,27

20250401

5

9 031

11 067,11

1

1

1,27

20250402

4

5 341

6 540,66

1

1

1,24

20250403

3

3 301

4 051,43

1

1

1,23

20250404

5

7 581

9 022,58

1

1

1,24

20250407

7

10 871

12 406,55

1

1

1,19

20250408

2

1 338

1 493,23

5

9 741

11 244,94

20250409

4

4 202

4 770,74

1

1

1,14

20250410

1

1

1,18

5

13 821

16 335,50

20250411

2

2 451

2 857,87

1

1

1,17

20250414

2

911

1 060,43

2

2

2,38

20250415

2

2 351

2 741,29

1

1

1,19

20250416

2

640

744,96

1

1

1,16

20250417

1

1

1,19

2

2 231

2 659,35

20250418

0

0

0,00

0

0

0,00

20250421

0

0

0,00

0

0

0,00

20250422

1

1

1,20

3

4 481

5 386,40

20250423

1

1

1,19

3

4 321

5 280,47

20250424

1

1

1,23

2

413

508,82

20250425

1

1

1,21

1

1

1,21

20250428

1

1

1,23

2

249

306,27

20250429

2

2

2,44

1

1

1,23

20250430

2

1 865

2 256,68

1

1

1,24

20250501

0

0

0,00

0

0

0,00

20250502

1

1

1,22

2

2 071

2 551,46

20250505

6

10 811

12 763,44

1

1

1,24

20250506

3

3 021

3 629,31

2

2

2,46

20250507

1

1

1,23

1

1

1,23

20250508

1

1

1,21

1

1

1,21

20250509

1

1

1,23

1

1

1,23

20250512

3

2 191

2 629,20

1

1

1,20

20250513

1

1

1,23

2

4

4,93

20250514

1

1

1,23

1

1

1,23

20250515

1

1

1,23

1

1

1,23

20250516

2

2 061

2 493,83

1

1

1,23

20250519

1

1

1,23

1

1

1,23

20250520

1

1

1,21

4

9 071

11 364,29

20250521

1

1

1,24

2

2

2,49

20250522

1

1

1,24

3

4 371

5 455,20

20250523

1

1

1,26

4

8 381

10 768,00

20250526

1

1

1,30

2

2 001

2 601,30

20250527

1

1

1,31

4

7 871

10 396,13

20250528

1

1

1,33

3

3 579

4 767,23

20250529

4

6 071

7 774,61

1

1

1,29

20250530

1

1

1,29

1

1

1,29

20250602

1

1

1,30

2

474

619,98

20250603

1

1

1,31

1

1

1,31

20250604

3

3 771

4 839,51

1

1

1,29

20250605

1

1

1,26

1

1

1,26

20250606

1

1

1,28

1

1

1,28

20250609

1

1

1,28

1

1

1,28

20250610

1

1

1,29

2

1 951

2 520,69

20250611

3

3 002

3 833,87

1

1

1,30

20250612

3

3 621

4 589,10

1

1

1,30

20250613

3

3 511

4 400,52

1

1

1,26

20250616

2

300

372,00

1

1

1,24

20250617

1

1

1,25

1

1

1,25

20250618

2

961

1 180,13

1

1

1,25

20250619

1

1

1,25

1

1

1,25

20250620

2

2 491

3 058,95

1

1

1,23

20250623

3

3 301

4 031,62

1

1

1,22

20250624

1

1

1,23

1

1

1,23

20250625

2

2 361

2 852,09

1

1

1,21

20250626

1

1

1,23

1

1

1,23

20250627

1

1

1,23

1

1

1,23

20250630

4

4 761

5 678,38

1

1

1,20

About ABIONYX Pharma

ABIONYX Pharma is a new-generation biotechnology company whose aim is to contribute to healthcare through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to offer drugs for the treatment of kidney and ophthalmological diseases, or new apoA-1 vectors used for targeted drug delivery.

Contacts

NewCap
Investor Relations
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Media Relations
Arthur Rouillé
abionyx@newcap.eu
+33 (0)1 44 71 00 15

ABIONYX Pharma

BOURSE:ABNX
Release Versions
EnglishFrench

Contacts

NewCap
Investor Relations
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Media Relations
Arthur Rouillé
abionyx@newcap.eu
+33 (0)1 44 71 00 15

More News From ABIONYX Pharma

ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 2nd Quarter 2025

TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today provides an update on its activity and cash position as of June 30, 2025. The activity dedicated to the discovery and development of innovative therapies, particularly in sepsis or the rare disease, LCAT deficien...

ABIONYX Pharma Announces the Start of Discussions With a Major Player in the Field of Sepsis for a Strategic Partnership

TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announced today that it has entered into discussions with a leading partner in sepsis. This player, recognized for its leadership in the healthcare field, is exploring with ABIONYX Pharma the establishment of a major c...

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

PARIS--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (Paris:ABNX) Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total voting rights Total gross (1) Total net (2) July 31, 2025 34,931,012 44,395,913 44,111,872 (1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shar...
Back to Newsroom